Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients

Figure 3

Relationship between the changes of frequencies of Th1, Treg, and DCs and HBsAg decline. (a) Changes of frequencies of Th1, Treg, and DCs were analyzed before and after treatment in patients with HBsAg decline ≥ 10% of C1-Group. BT: before treatment; AT: after treatment. (b) Changes of frequencies of Th1, Treg, and DCs were analyzed before and after treatment in patients with HBsAg decline ≥ 10% of T1-Group. (c) Changes of frequencies of Th1, Treg, and DCs were analyzed before and after treatment in patients with HBsAg decline ≥ 10% of C2-Group. (d) Changes of frequencies of Th1, Treg, and DCs were analyzed before and after treatment in patients with HBsAg decline ≥ 10% of T2-Group.

(a) Patients with HBsAg decline ≥ 10% in C1-Group

(b) Patients with HBsAg decline ≥ 10% in T1-Group

(c) Patients with HBsAg decline ≥ 10% in C2-Group

(d) Patients with HBsAg decline ≥ 10% in T2-Group